Effects of TZD Use and Discontinuation on Fracture Rates in ACCORD Bone Study.
暂无分享,去创建一个
E. Vittinghoff | J. Williamson | W. Ambrosius | D. Bauer | D. Bonds | A. Sood | A. Schwartz | K. Margolis | R. Cohen | D. Sellmeyer | M. Banerji | R. Josse | Haiying Chen | T. Isakova | B. Hamilton | D. Simmons | A. Shibli-Rahhal | Adrian M. Schnall
[1] Yun-fa Jiang,et al. Risk of fracture with thiazolidinediones: an updated meta-analysis of randomized clinical trials. , 2014, Bone.
[2] I. Reid,et al. The skeletal effects of pioglitazone in type 2 diabetes or impaired glucose tolerance: a randomized controlled trial. , 2014, European journal of endocrinology.
[3] Alfonso T. Perez,et al. Effects of pioglitazone on bone in postmenopausal women with impaired fasting glucose or impaired glucose tolerance: a randomized, double-blind, placebo-controlled study. , 2013, The Journal of clinical endocrinology and metabolism.
[4] J. Cauley,et al. Public health impact of osteoporosis. , 2013, The journals of gerontology. Series A, Biological sciences and medical sciences.
[5] R. Guldberg,et al. The Effect of Rosiglitazone on Bone Mass and Fragility Is Reversible and Can Be Attenuated With Alendronate , 2013, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[6] R. Eastell,et al. Rosiglitazone decreases bone mineral density and increases bone turnover in postmenopausal women with type 2 diabetes mellitus. , 2013, The Journal of clinical endocrinology and metabolism.
[7] E. Vittinghoff,et al. Intensive Glycemic Control Is Not Associated With Fractures or Falls in the ACCORD Randomized Trial , 2012, Diabetes Care.
[8] L. Hofbauer,et al. Bone, sweet bone—osteoporotic fractures in diabetes mellitus , 2012, Nature Reviews Endocrinology.
[9] J. Bilezikian,et al. A randomized, parallel group, double‐blind, multicentre study comparing the efficacy and safety of Avandamet (rosiglitazone/metformin) and metformin on long‐term glycaemic control and bone mineral density after 80 weeks of treatment in drug‐naïve type 2 diabetes mellitus patients , 2011, Diabetes, obesity & metabolism.
[10] Z. Rosenwaks,et al. Rosiglitazone and Pioglitazone Inhibit Estrogen Synthesis in Human Granulosa Cells by Interfering with Androgen Binding to Aromatase , 2011, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.
[11] A. C. Yazici,et al. ORIGINAL ARTICLE: Effects of rosiglitazone on bone mineral density and remodelling parameters in Postmenopausal diabetic women: a 2‐year follow‐up study , 2010, Clinical endocrinology.
[12] Ian J. Douglas,et al. The Risk of Fractures Associated with Thiazolidinediones: A Self-controlled Case-Series Study , 2009, PLoS medicine.
[13] M. Hanefeld,et al. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial , 2009, The Lancet.
[14] C. Furberg,et al. Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis , 2009, Canadian Medical Association Journal.
[15] J. Dormandy,et al. Safety and Tolerability of Pioglitazone in High-Risk Patients with Type 2 Diabetes , 2009, Drug safety.
[16] Michael E. Miller,et al. Effects of intensive glucose lowering in type 2 diabetes. , 2008, The New England journal of medicine.
[17] A. Hermann,et al. Association of pioglitazone treatment with decreased bone mineral density in obese premenopausal patients with polycystic ovary syndrome: a randomized, placebo-controlled trial. , 2008, The Journal of clinical endocrinology and metabolism.
[18] H. Jick,et al. Use of thiazolidinediones and fracture risk. , 2008, Archives of internal medicine.
[19] E. Tuzcu,et al. Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial. , 2008, JAMA.
[20] B. Zinman,et al. Rosiglitazone-Associated Fractures in Type 2 Diabetes , 2008, Diabetes Care.
[21] D. Goff,et al. Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods. , 2007, The American journal of cardiology.
[22] I. Reid,et al. The peroxisome proliferator-activated receptor-gamma agonist rosiglitazone decreases bone formation and bone mineral density in healthy postmenopausal women: a randomized, controlled trial. , 2007, The Journal of clinical endocrinology and metabolism.
[23] P. Vestergaard,et al. Discrepancies in bone mineral density and fracture risk in patients with type 1 and type 2 diabetes—a meta-analysis , 2007, Osteoporosis International.
[24] Charles E. McCulloch,et al. Regression Methods in Biostatistics: Linear, Logistic, Survival, and Repeated Measures Models , 2005 .
[25] C. Cooper,et al. Use of Oral Corticosteroids and Risk of Fractures , 2000 .
[26] E. Simpson,et al. Peroxisome Proliferator-activated Receptor γ Ligands Inhibit Estrogen Biosynthesis in Human Breast Adipose Tissue: Possible Implications for Breast Cancer Therapy , 2000 .
[27] E White,et al. The effect of misclassification of disease status in follow-up studies: implications for selecting disease classification criteria. , 1986, American journal of epidemiology.